<?xml version='1.0' encoding='utf-8'?>
<document id="21480191"><sentence text="Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors."><entity charOffset="21-31" id="DDI-PubMed.21480191.s1.e0" text="colchicine" /><entity charOffset="80-90" id="DDI-PubMed.21480191.s1.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.21480191.s1.e0" e2="DDI-PubMed.21480191.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21480191.s1.e0" e2="DDI-PubMed.21480191.s1.e1" /></sentence><sentence text="Drug-drug interactions can limit the safety of colchicine for treating rheumatic diseases"><entity charOffset="47-57" id="DDI-PubMed.21480191.s2.e0" text="colchicine" /></sentence><sentence text=" Seven separate drug-drug interaction (DDI) studies were performed to elucidate the in vivo effects of concomitant treatment with colchicine and known inhibitors of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil ER [extended release]), and diltiazem ER) on the pharmacokinetics of colchicine"><entity charOffset="130-140" id="DDI-PubMed.21480191.s3.e0" text="colchicine" /><entity charOffset="210-222" id="DDI-PubMed.21480191.s3.e1" text="cyclosporine" /><entity charOffset="224-236" id="DDI-PubMed.21480191.s3.e2" text="ketoconazole" /><entity charOffset="238-247" id="DDI-PubMed.21480191.s3.e3" text="ritonavir" /><entity charOffset="249-263" id="DDI-PubMed.21480191.s3.e4" text="clarithromycin" /><entity charOffset="265-277" id="DDI-PubMed.21480191.s3.e5" text="azithromycin" /><entity charOffset="358-368" id="DDI-PubMed.21480191.s3.e6" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e0" e2="DDI-PubMed.21480191.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e0" e2="DDI-PubMed.21480191.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e0" e2="DDI-PubMed.21480191.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e0" e2="DDI-PubMed.21480191.s3.e3" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e0" e2="DDI-PubMed.21480191.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e0" e2="DDI-PubMed.21480191.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e0" e2="DDI-PubMed.21480191.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e1" e2="DDI-PubMed.21480191.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e1" e2="DDI-PubMed.21480191.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e1" e2="DDI-PubMed.21480191.s3.e3" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e1" e2="DDI-PubMed.21480191.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e1" e2="DDI-PubMed.21480191.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e1" e2="DDI-PubMed.21480191.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e2" e2="DDI-PubMed.21480191.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e2" e2="DDI-PubMed.21480191.s3.e3" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e2" e2="DDI-PubMed.21480191.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e2" e2="DDI-PubMed.21480191.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e2" e2="DDI-PubMed.21480191.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e3" e2="DDI-PubMed.21480191.s3.e3" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e3" e2="DDI-PubMed.21480191.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e3" e2="DDI-PubMed.21480191.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e3" e2="DDI-PubMed.21480191.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e4" e2="DDI-PubMed.21480191.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e4" e2="DDI-PubMed.21480191.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e4" e2="DDI-PubMed.21480191.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e5" e2="DDI-PubMed.21480191.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21480191.s3.e5" e2="DDI-PubMed.21480191.s3.e6" /></sentence><sentence text=" The objective was to develop colchicine-dosing algorithms with improved safety"><entity charOffset="30-40" id="DDI-PubMed.21480191.s4.e0" text="colchicine" /></sentence><sentence text="" /><sentence text="All studies were open-label, non-randomized, single-center, one-sequence, two-period DDI experiments, using two 0" /><sentence text="6-mg doses of colchicine, separated by a minimum 14-day washout period, followed by administration of the approved on-label regimen of known CYP3A4/P-glycoprotein inhibitors"><entity charOffset="14-24" id="DDI-PubMed.21480191.s7.e0" text="colchicine" /></sentence><sentence text=" Plasma concentrations of colchicine, but not the reference CYP3A4/P-glycoprotein inhibitors, were determined, and the pharmacokinetic parameters were calculated"><entity charOffset="26-36" id="DDI-PubMed.21480191.s8.e0" text="colchicine" /></sentence><sentence text="" /><sentence text="The ratios of the maximum concentration and area under the curve from time 0 to infinity for colchicine plus CYP3A4/P-glycoprotein inhibitors versus colchicine alone were &gt;125% across all studies, with the exception of studies involving azithromycin"><entity charOffset="93-103" id="DDI-PubMed.21480191.s10.e0" text="colchicine" /><entity charOffset="149-159" id="DDI-PubMed.21480191.s10.e1" text="colchicine" /><entity charOffset="237-249" id="DDI-PubMed.21480191.s10.e2" text="azithromycin" /><pair ddi="false" e1="DDI-PubMed.21480191.s10.e0" e2="DDI-PubMed.21480191.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21480191.s10.e0" e2="DDI-PubMed.21480191.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21480191.s10.e0" e2="DDI-PubMed.21480191.s10.e2" /><pair ddi="false" e1="DDI-PubMed.21480191.s10.e1" e2="DDI-PubMed.21480191.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21480191.s10.e1" e2="DDI-PubMed.21480191.s10.e2" /></sentence><sentence text=" Significant DDIs were present when single doses of colchicine were coadministered with most of the selected CYP3A4/P-glycoprotein inhibitors"><entity charOffset="52-62" id="DDI-PubMed.21480191.s11.e0" text="colchicine" /></sentence><sentence text=" Recommended colchicine dose reductions of 33-66% for the treatment of acute gout and 50-75% for prophylaxis were calculated for concomitant therapy with each agent, with the exception of no dose adjustment when colchicine is used in combination with azithromycin"><entity charOffset="13-23" id="DDI-PubMed.21480191.s12.e0" text="colchicine" /><entity charOffset="212-222" id="DDI-PubMed.21480191.s12.e1" text="colchicine" /><entity charOffset="251-263" id="DDI-PubMed.21480191.s12.e2" text="azithromycin" /><pair ddi="false" e1="DDI-PubMed.21480191.s12.e0" e2="DDI-PubMed.21480191.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21480191.s12.e0" e2="DDI-PubMed.21480191.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21480191.s12.e0" e2="DDI-PubMed.21480191.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21480191.s12.e1" e2="DDI-PubMed.21480191.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21480191.s12.e1" e2="DDI-PubMed.21480191.s12.e2" /></sentence><sentence text="" /><sentence text="These studies provide quantitative evidence regarding drug interactions and necessary adjustments in the dose of colchicine if colchicine treatment is continued during therapy with multiple CYP3A4/P-glycoprotein inhibitors"><entity charOffset="113-123" id="DDI-PubMed.21480191.s14.e0" text="colchicine" /><entity charOffset="127-137" id="DDI-PubMed.21480191.s14.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.21480191.s14.e0" e2="DDI-PubMed.21480191.s14.e0" /><pair ddi="false" e1="DDI-PubMed.21480191.s14.e0" e2="DDI-PubMed.21480191.s14.e1" /></sentence><sentence text=" We demonstrated the need for specific reductions in the dose of colchicine when it is used in combination with 2 broadly prescribed calcium channel blockers (verapamil ER and diltiazem ER) and that the dose of colchicine does not need to be adjusted when it is used in combination with azithromycin"><entity charOffset="65-75" id="DDI-PubMed.21480191.s15.e0" text="colchicine" /><entity charOffset="133-140" id="DDI-PubMed.21480191.s15.e1" text="calcium" /><entity charOffset="211-221" id="DDI-PubMed.21480191.s15.e2" text="colchicine" /><entity charOffset="287-299" id="DDI-PubMed.21480191.s15.e3" text="azithromycin" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e0" e2="DDI-PubMed.21480191.s15.e0" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e0" e2="DDI-PubMed.21480191.s15.e1" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e0" e2="DDI-PubMed.21480191.s15.e2" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e0" e2="DDI-PubMed.21480191.s15.e3" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e1" e2="DDI-PubMed.21480191.s15.e1" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e1" e2="DDI-PubMed.21480191.s15.e2" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e1" e2="DDI-PubMed.21480191.s15.e3" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e2" e2="DDI-PubMed.21480191.s15.e2" /><pair ddi="false" e1="DDI-PubMed.21480191.s15.e2" e2="DDI-PubMed.21480191.s15.e3" /></sentence><sentence text="" /></document>